Germ Cell Tumor-Specific CAR Construction Service

Online Inquiry

Background Service Workflow Highlights FAQs Contact Products

Are you currently facing challenges with limited treatment options for advanced germ cell tumors or difficulties in developing highly specific and effective immunotherapies for solid malignancies? Our germ cell tumor-specific CAR construction service helps you develop cutting-edge, targeted cellular therapies and overcome solid tumor complexities through advanced CAR engineering, cytokine armoring, and rigorous functional validation.

Introduction

Germ cell tumor (GCT) is a rare kind of cancer that derives from germ cells, which can be benign or malignant (cancer). The etiology of germ cell tumors is still unclear. The treatment for germ cell tumors usually includes surgery, chemotherapy, radiation, bone marrow transplantation, or a combination of these approaches. However, these traditional treatments are not highly effective and can cause the risk of potential complications. In recent decades, GCT therapy has focused on adaptive immunotherapy, such as chimeric antigen receptor (CAR)-engineered T cells or NK cells, which have been showing remarkable promise for treating cancer. Creative Biolabs, as a leading technology provider, offers a variety of CARs targeting GCT-specific antigens.

Fig.1 A variety of CAR cell therapies to destroy tumors. (OA Literature) Fig.1 Multiple CAR cell therapies destroy tumors.¹

Germ Cell Tumor-Specific CAR Construction Service at Creative Biolabs

Creative Biolabs offers a comprehensive germ cell tumor-specific CAR construction service designed to empower your oncology research and therapeutic development. We provide highly tailored solutions, from novel antigen identification to the delivery of fully validated CAR constructs, ensuring your project benefits from precision engineering and deep scientific expertise. Our service is meticulously structured to address the unique challenges of solid tumors, aiming for enhanced efficacy and reduced off-target toxicity.

Creative Biolabs provides customers with cutting-edge CAR against a series of germ cell tumor-specific antigens, which is based on a great amount of research and many years of experience. As a reputable service provider, we are dedicated to highly tailored service in order to meet your unique requirements.

Service Process

The workflow of germ cell tumor-specific CAR construction service. (Creative Biolabs Original)

Key Advantages

Tailored CAR Design & Optimization: Highly customized CARs with affinity-tuned scFvs, optimized hinge/transmembrane domains, and selected co-stimulatory signals to maximize functionality and minimize off-target effects against GCTs.
Cytokine Armoring: Integration of IL-21 to boost CAR cell persistence, metabolic fitness, and cytotoxic function for GCT microenvironments.
Flexible Cell Platforms: Capabilities across CAR-T, CAR-NK, and CAR-Macrophages for diverse GCT therapy options.
End-to-End Support: Seamless service from target identification and CAR design to preclinical in vitro/in vivo validation to accelerate GCT research.

FAQs

Q1: What types of germ cell tumor antigens can you target?

A1: We can target a wide range of germ cell tumor-associated antigens. Our service begins with a thorough analysis of your specific target(s) of interest to ensure optimal specificity and efficacy. If you have a novel antigen in mind or need assistance in identifying suitable targets, our expert team is ready to collaborate. Please feel free to inquire for a detailed discussion about your target antigen needs.

Q2: How do you ensure the CARs are specific to tumor cells and avoid healthy tissue?

A2: We employ advanced strategies to enhance tumor specificity. This includes meticulous scFv affinity tuning to discriminate between high and low antigen expression, and the development of innovative CAR formats like Compound CARs (cCARs), which require the presence of multiple tumor antigens for activation. We also consider engineering approaches to mitigate off-target effects.

Q3: What are the advantages of your CARs in overcoming the solid tumor microenvironment?

A3: Our CAR designs incorporate features specifically aimed at overcoming the challenges of the solid tumor microenvironment. This includes optimizing hinge and transmembrane domains for efficient synapse formation and armoring CAR cells with cytokines like Interleukin-21 (IL-21) to enhance their persistence, metabolic fitness, and cytotoxic function within the hostile TME.

Why Choose Us?

Creative Biolabs stands as a leader in the field of adoptive cell therapy, offering unparalleled expertise and innovative solutions for germ cell tumor-specific CAR construction. Our commitment to scientific excellence and client success sets us apart.

Customer Reviews

"The CAR-NK cells engineered by Creative Biolabs showed remarkable persistence in our in vivo models, a critical factor for solid tumor therapy. Their cytokine armoring strategy, particularly with IL-21, truly made a difference in overcoming the immunosuppressive tumor microenvironment." - Prof. L***a M.

"We were particularly impressed with the depth of their validation, including phosphoproteomics and RNA-seq. This level of detail from Creative Biolabs' CAR Construction Service provided crucial insights into CAR signaling and helped us understand the differentiation and memory potential of our engineered cells." - Dr. P***r J.

How to Contact Us

Ready to revolutionize GCT treatment with advanced CAR therapy? Our team of experienced scientists is eager to discuss your project and provide a customized solution.

For more information or to discuss your specific project, please reach out to our team.

Products ordering information

Please note: Besides the CARs targeting GCT-specific antigens listed below, we also provide highly customized service tailored to your research, diagnostic and therapeutic application purposes. We look forward to hearing from you.

Associated malignancy	Target antigen	Receptor type	Product
Ovarian cancer	mesothelin	scFv-CD28-41BB-CD3ζ	CAR-T-3-M321-2BZ
	FRα	scFv-CD28-41BB-CD3ζ	CAR-T-3-M313-2BZ
	Bpep	scFv-CD28-41BB-CD3ζ	CAR-T-3-M402-2BZ
	CLDN6	scFv-CD28-41BB-CD3ζ	CAR-LC192
	B7-H4	scFv--CD28-CD3ζ	CAR-LC240
	LHR	scFv-CD28-41BB-CD3ζ	CAR-LC249
	MUC16	scFv-ICOS-4-1BB-CD3ζ	CAR-SB-02LX544
	NKG2D ligands	NKG2D receptor-CD28-CD3ζ	CAR-MZ233

Reference

Liu, Yan et al. “CAR-armored-cell therapy in solid tumor treatment.” Journal of translational medicine vol. 22,1 1076. 28 Nov. 2024, https://doi.org/10.1186/s12967-024-05903-3. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.